Pediatric Studies of Adult Drugs
MIKAELA NAYLON GIVE KIDS A CHANCE ACT, Public Law No. 119-75
February 3, 2026,
140 STAT. 173
The Mikaela Naylon Give Kids a Chance Act was passed into law in as part of the Consolidated Appropriations Act of 2026 in on February 3, 2026.
PUBLIC LAW NO. 119-75
DIVISION J—HEALTH CARE EXTENDERS , TITLE VI — FOOD AND DRUG ADMINISTRATION
Subtitle: Subtitle A — Mikaela Naylon Give Kids a Chance Act
Sec. 6604: Reauthorization of the Rare Pediatric Disease PRV Program
The law formally extends the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program through September 30, 2029.
The Incentive: Sponsors who successfully develop and gain approval for a drug targeting a rare pediatric disease receive a transferable priority review voucher.
Value: This voucher permits the recipient to fast-track the FDA review of a future, separate drug application down to 6 months rather than the standard 10 months. Because these vouchers can be legally sold to other pharmaceutical companies, they serve as a powerful financial catalyst to fund pediatric pipeline research.
Sec 6601: Molecularly Targeted Pediatric Cancer Combination Investigations
The law updates both the Research Equity Act (PREA) and the RACE for Children Act frameworks by expanding the FDA's authority regarding pediatric oncology trials.
Combination Therapies: The FDA is granted explicit authority to require drug developers to study new cancer drugs in combination with other active ingredients (such as adult-approved therapies or standard-of-care treatments).
The Impact: Historically, requirements were locked to single-agent pathways, meaning children lagged years behind adults in gaining access to multi-drug oncology regimens.
Sec. 6602: Civil penalties for failing to complete required pediatric trials under PREA.
The package incorporates components from the Innovation in Pediatric Drugs Act to increase enforcement of mandatory pediatric testing.
Enforcement Leverage: If a drug sponsor fails to complete their pediatric trial requirements under PREA, the FDA can take direct action if the sponsor demonstrates a "lack of due diligence".
Penalties: The agency can treat non-compliance with the same weight as other post-market violations, eliminating the standard delays that occur when companies deprioritize childhood tracking.
Sec. 6504. Program for pediatric study of drugs
The bill directs $25 million annually for fiscal years 2026 through 2028 out of designated National Institutes of Health (NIH) funds. This money is specifically earmarked to support priority research and trials evaluating pediatric drug safety and efficacy.
Section 6605: Interpretation of orphan drug exclusivity.
The Mikaela Naylon Give Kids a Chance Act explicitly replaces the long-contested statutory phrase “same disease or condition” in the Orphan Drug Act with “same approved use or indication within such rare disease or condition”. The amendment is retroactive in scope and applies retroactively to all orphan drugs regardless of their initial designation or approval date,.